SOFTWAVE TISSUE REGENERATION TEC

Softwave Tissue Regeneration Technologies, LLC specializes in the design, development, and deployment of advanced electromedical devices for regenerative therapy, with a focused expertise in extracorporeal shockwave technology (ESWT). The company manufactures FDA-regulated, non-invasive therapeutic systems that deliver controlled acoustic energy to stimulate tissue repair, reduce chronic pain, and accelerate healing in musculoskeletal and urological applications. Their technical proficiency spans precision waveform engineering, piezoelectric transducer integration, real-time energy modulation, and clinical-grade device calibration compliant with IEC 60601 standards. Differentiators include proprietary tissue-targeting algorithms and modular platform architectures that enable rapid adaptation for military, veteran, and civilian clinical environments. The contractor maintains a strong, consistent relationship with the Department of Defense and the Department of Veterans Affairs, delivering specialized shockwave therapy systems tailored for combat-related injuries, chronic tendonopathies, and post-traumatic rehabilitation. Work for these agencies centers on field-deployable, ruggedized medical devices that meet military operational requirements and VA clinical protocols for pain management and tissue regeneration. Operating under NAICS 334510, the firm is deeply embedded in the electromedical equipment manufacturing sector, serving the growing demand for non-pharmacological, non-surgical interventions in orthopedics, urology, and sports medicine. Their market positioning is defined by clinical efficacy, regulatory compliance, and mission-specific customization for high-acuity care settings. As a small business structured as a 2L entity based in Kennesaw, Georgia, Softwave Tissue Regeneration Technologies, LLC operates without federal certifications but maintains a focused presence in the defense and veteran healthcare markets. The company’s geographic footprint and technical specialization position it as a niche provider of advanced therapeutic devices for federal medical programs requiring precision, reliability, and rapid deployment.